•  
  •  
  •  
  •  

2026-07-19 23:26:30

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Federal Bank Consolidated Net Profit Jumps 36.8% YoY to ₹1,256 Crore in Q1 FY27
  • The Monarch Surveyors and Engineering Consultants Ltd receives order worth Rs. 2.53 crores
  • PNGS Gargi Fashion Jewellery Ltd opens new store at Raipur
  • Central Bank of India Net Profit Rises to ₹1,323 Crore in Q1 FY27, Asset Quality Remains Stable
  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg

Keywords Selected:  RepoRate

Research

  • SBI Capital Markets: RBI Monetary Policy Dec'24 - RBI faces arduous task of managing all dynamics: Liquidity, Currency, Growth and Inflation
  • Monetary Policy Update - September 2022 - ICICI Direct
  • RBI's repo rate increase of 50 bps - the third in a row in line with our expectations
  • Acuité continues to expect the RBI to hike repo rate by 50 bps in FY23 - RBI MPC April'22
  • RBI retains accommodative stance for now, revises it's inflation and growth forecast for FY23 upwards
  • RBI plays it cautious, repo rates unchanged - Anuj Puri, Chairman - ANAROCK Group

Market Commentary

  • Unchanged Repo Rate Supports Affordability, Confidence in Housing Market

Stock Report

  • Indian Bank revises Lending Rate linked with Policy Repo Rate

Latest Post

  • Federal Bank Consolidated Net Profit Jumps 36.8% YoY to ₹1,256 Crore in Q1 FY27
  • The Monarch Surveyors and Engineering Consultants Ltd receives order worth Rs. 2.53 crores
  • PNGS Gargi Fashion Jewellery Ltd opens new store at Raipur
  • Central Bank of India Net Profit Rises to ₹1,323 Crore in Q1 FY27, Asset Quality Remains Stable
  • Alembic Pharmaceuticals Limited's Partner NATCO Pharma Limited receives USFDA Tentative Approval for Olaparib Tablets, 100 mg and 150 mg


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2025